Copyright
©The Author(s) 2024.
World J Transplant. Mar 18, 2024; 14(1): 89978
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.89978
Published online Mar 18, 2024. doi: 10.5500/wjt.v14.i1.89978
Table 1 Pre-transplant screening and diagnostic work-up for kidney transplant recipients
CMV | CMV IgG serology in both donors and recipients |
EBV | Screening by EBV serology in both donors and recipients |
BKPyV | Not done at present |
HSV | HSV antibodies in blood |
VZV | Pretransplant screening for previous VZV infectio |
Hepatitis B & C | HBV |
HBsAg and antibody to hepatitis B core antigen (antiHBc) | |
HCV | |
HCV antibody test | |
Respiratory viruses | Nasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence |
Table 2 Post-transplant screening and diagnostic work-up for kidney transplant recipients
CMV | Quantitative CMV viral load |
Diagnosis- presence of CMV DNA in whole blood or plasma | |
Tissue biopsy | |
Diagnosis- presence of CMV inclusion or immunostaining | |
CMV serology | |
Diagnosis- presence of CMV IgG post kidney transplantation in | |
CMV R- patients | |
EBV | Quantitative EBV viral load |
Tissue biopsy | |
EBV serology | |
BKPyV | Urine cytology |
Quantitative BK viral load in urine | |
Quantitative BK viral load in plasma | |
Allograft biopsy | |
HSV | Direct fluorescence antibody for HSV from vesicular lesions or PCR from CSF or visceral tissue samples |
VZV | Direct fluorescence antibody for VZV from vesicular lesions or PCR from CSF or visceral tissue samples |
Hepatitis B & C | HBV |
HBsAg and antibody to hepatitis B core antigen (antiHBc) | |
HCV | |
HCV antibody test | |
Respiratory viruses | Nasopharyngeal wash or bronchoalveolar lavage fluid (BAL) specimens, (in the case of Adeno virus - stools or plasma), by conventional viral culture, PCR, or direct immunofluorescence |
Table 3 Treatment of viral infections kidney transplant recipients
CMV | CMV load copy no < 500 - below quantifiable level - no action |
CMV load copy no 500-3000 - active CMV infection - repeat CMV in 1 week, consider treatment if clinically indicated | |
CMV load copy no > 3000 - Active CMV infection - commence pre-emptive treatment | |
Intravenous ganciclovir or oral valganciclovir | |
EBV | Immunosuppressive drug reduction |
Ganciclovir and valganciclovir have antiviral impact against EBV | |
BKPyV | Immunosuppressive drug reduction |
No specific antiviral therapy | |
HSV | Acyclovir |
Intravenous or oral | |
VZV | Intravenous acyclovir, while less severe infection can be treated with oral acyclovir |
Hepatitis B & C | Immunosuppressive drug reduction |
Hepatitis B – Lamivudine | |
Hepatitis C - IFN and ribavirin | |
Respiratory viruses | Reduce immunosuppressive drugs |
Supportive care and, in some cases, the use of antivirals |
Table 4 Prevention of viral infections kidney transplant recipients
CMV | Valganciclovir |
Universal prophylaxis - Dose (mg) = (7 × BSA × eGFR) once a day | |
Preemptive therapy - Dose (mg) = ( 7 × BSA × eGFR) bd | |
EBV | EBV viral load surveillance and preemptive therapy for EBV mismatched patients |
BKPyV | BK viral load monitoring and early identification of BK viremia |
HSV | Avoidance of visitors or health professionals who have HSV signs and symptoms |
VZV | Avoidance of visitors or health professionals who have VZV signs and symptoms. Vaccination including family members |
Hepatitis B & C | Hepatitis B vaccination and immunity verified with Hepatitis B surface antibody screening following completion of the vaccination series |
Respiratory viruses | Avoidance of other individuals who have signs or symptoms of infection, hand hygiene, and use of droplet precautions for those suspected of having infection |
- Citation: Ranawaka R, Dayasiri K, Sandamali E, Gamage M. Management strategies for common viral infections in pediatric renal transplant recipients. World J Transplant 2024; 14(1): 89978
- URL: https://www.wjgnet.com/2220-3230/full/v14/i1/89978.htm
- DOI: https://dx.doi.org/10.5500/wjt.v14.i1.89978